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Because they kill sensitive organisms, anti-infective agents
are bound to exert an evolutionary pressure toward the
emergence and spread of resistance mechanisms. Com-
mon to all infectious diseases, this vicious circle is espe-
cially acute for malaria. P. falciparum resistance to
chloroquine and sulfadoxine-pyrimethamine became so
widespread that these former first-line treatments had to
be abandoned [1]. Today, in certain areas, P. falciparum
parasites appear to gradually lose their sensitivity to arte-
misinin derivatives, on which are based the current thera-
pies for both uncomplicated and severe P. falciparum
malaria [2,3]. New classes of antimalarial medicine are
urgently needed to stay ahead in the resistance arms race.
These should be designed not only to overcome existing
resistance mechanisms, but also to prevent the emergence
of de novo resistance for as along as possible.
Cell-based screening methods have led to a renaissance
of new classes of anti-malarial compounds [4], offering
us the potential to select and modify molecules based on
their resistance potential. In order to quantitatively assess
this potential in P. falciparum, we developed a standar-
dized ex vivo methodology that can be applied during the
early phases of the drug development process. Cross-
resistance is evaluated through a panel of specific multi-
drug resistant strains designed to cover all genetically
validated resistance mechanisms known to occur in the
field. Second, the genetic ability of P. falciparum to
evolve a genetically encoded resistance mechanism is
quantified by measuring the minimal inoculum for resis-
tance (MIR), that is the minimal number of parasite from
which a resistant mutant is likely to be selected ex vivo
by a constant low level of drug pressure. Further, the
generation of resistant parasites possibly facilitates the
understanding of the compound mode-of-action and per-
mits the identification of resistance markers, which are
essential for resistance monitoring during the clinical
development and post-marketing surveillance phases.
Altogether, these and other parameters, such as resistant
parasite fitness and gametocyte production, define a com-
prehensive profile, which allows the identification of overt
risks and the active prioritization of the most robust anti-
malarials in a cost-effective manner.
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